Abstract
Hepatitis C virus (HCV) infection among injecting drug users (IDUs) is a major public health concern. It is important to know the current burden of HCV infection among IDUs for targeted public health interventions in this high risk population. We systematically reviewed the published literature on prevalence of HCV infections among IDUs between January 1989 and April 2014. Sixty studies met the inclusion criteria for the review and subsequent analysis. Among the selected studies 26,311 IDUs were assessed for HCV infection of which 16,231 were positive, giving an overall prevalence of 61.7% (95% Confidence Interval [95% CI] 61.1-62.3%). Of the selected studies, 21 were from Asia, 20 from Europe, 13 from Americas, 5 from Australia and one from Africa. Combined regional estimates of HCV prevalence among IDUs showed that Africa has the highest mean prevalence of HCV among IDUs (97.3%, 95% CI 95.5-98.4%), however, this estimate was based only on one study from Mauritius. Europe has the second highest mean prevalence (65.9%, 95% CI 64.9-66.9%) followed by Australia (56.5%, 95% CI 53.8-59.2%). Our review suggests that the prevalence of HCV among IDUs is significantly high. There are very limited data from African nations. More comprehensive understanding of HCV epidemiology among IDUs including the risk behaviours are needed for this high risk group.
Keywords: Hepatitis C virus, intravenous drug user, prevalence study, risk behaviour, targeted public health intervention.
Infectious Disorders - Drug Targets
Title:Current Burden of Hepatitis C Virus Infection Among Injecting Drug Users: A Mini Systematic Review of Prevalence Studies
Volume: 14 Issue: 2
Author(s): Shafquat Mohammed Rafiq, Gouri Rani Banik, Sabina Khan, Harunor Rashid and Gulam Khandaker
Affiliation:
Keywords: Hepatitis C virus, intravenous drug user, prevalence study, risk behaviour, targeted public health intervention.
Abstract: Hepatitis C virus (HCV) infection among injecting drug users (IDUs) is a major public health concern. It is important to know the current burden of HCV infection among IDUs for targeted public health interventions in this high risk population. We systematically reviewed the published literature on prevalence of HCV infections among IDUs between January 1989 and April 2014. Sixty studies met the inclusion criteria for the review and subsequent analysis. Among the selected studies 26,311 IDUs were assessed for HCV infection of which 16,231 were positive, giving an overall prevalence of 61.7% (95% Confidence Interval [95% CI] 61.1-62.3%). Of the selected studies, 21 were from Asia, 20 from Europe, 13 from Americas, 5 from Australia and one from Africa. Combined regional estimates of HCV prevalence among IDUs showed that Africa has the highest mean prevalence of HCV among IDUs (97.3%, 95% CI 95.5-98.4%), however, this estimate was based only on one study from Mauritius. Europe has the second highest mean prevalence (65.9%, 95% CI 64.9-66.9%) followed by Australia (56.5%, 95% CI 53.8-59.2%). Our review suggests that the prevalence of HCV among IDUs is significantly high. There are very limited data from African nations. More comprehensive understanding of HCV epidemiology among IDUs including the risk behaviours are needed for this high risk group.
Export Options
About this article
Cite this article as:
Rafiq Shafquat Mohammed, Banik Gouri Rani, Khan Sabina, Rashid Harunor and Khandaker Gulam, Current Burden of Hepatitis C Virus Infection Among Injecting Drug Users: A Mini Systematic Review of Prevalence Studies, Infectious Disorders - Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1871526514666141014145612
DOI https://dx.doi.org/10.2174/1871526514666141014145612 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polysarcosine: The Best Alternative of Poly (Ethylene Glycol)
Current Applied Polymer Science Aporphine Alkaloids and their Antioxidant Medical Application: From Antineoplastic Agents to Motor Dysfunction Diseases
Current Organic Chemistry Does A Subclinical Cardiotoxic Effect of Clozapine Exist? Results from a Follow-up Pilot Study
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Immunotherapy in Central Nervous System)
Current Pharmaceutical Biotechnology Impact of Tracer Retention Levels on Visual Analysis of Cerebral [<sup>18</sup>F]- Florbetaben Pet Images
Current Radiopharmaceuticals Whole Brain Atrophy and Sample Size Estimate via Iterative Principal Component Analysis for Twelve-month Alzheimer's Disease Trials
Neuroscience and Biomedical Engineering (Discontinued) Cholinergic Drugs as Therapeutic Tools in Inflammatory Diseases: Participation of Neuronal and Non-Neuronal Cholinergic Systems.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Current Drug Targets - Inflammation & Allergy Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Protein & Peptide Letters Cyclopeptide Analogs for Generating New Molecular and 3D Diversity
Combinatorial Chemistry & High Throughput Screening Mindfulness in the Treatment of Adolescents with Problem Substance Use
Adolescent Psychiatry Role of Diet and Nutrition on the Alteration of the Quality and Quantity of Stem Cells in Human Aging and the Diseases of Aging
Current Pharmaceutical Design Serum Bilirubin after Acute Ischemic Stroke is Associated with Stroke Severity
Current Neurovascular Research Studying the Human Gut Microbiota in the Trans-Omics Era - Focus on Metagenomics and Metabonomics
Current Pharmaceutical Design Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions
Drug Metabolism Letters Ethical Implications for Clinical Practice and Future Research in “At Risk” Individuals
Current Pharmaceutical Design Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment
Current Pharmaceutical Design Agroecological Strategies for Arthropod Pest Management in Brazil
Recent Patents on Food, Nutrition & Agriculture The ERK 1 and 2 Pathway in the Nervous System: From Basic Aspects to Possible Clinical Applications in Pain and Visceral Dysfunction
Current Neuropharmacology A Chemical Genetics Approach for Specific Differentiation of Stem Cells to Somatic Cells: A New Promising Therapeutical Approach
Combinatorial Chemistry & High Throughput Screening